- Record: found
- Abstract: not found
- Article: not found
Erdheim-Chester disease harboring the BRAF V600E mutation.
2012-11-10
Antineoplastic Combined Chemotherapy Protocols, therapeutic use, Benzamides, Biological Markers, metabolism, Erdheim-Chester Disease, diagnosis, drug therapy, genetics, Glutamic Acid, Humans, Immunohistochemistry, Interferon-alpha, administration & dosage, Male, Middle Aged, Mutation, Piperazines, Prednisolone, Proto-Oncogene Proteins B-raf, Pyrimidines, Receptor, Platelet-Derived Growth Factor beta, Valine
Read this article at
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Related collections
Author and article information
Antineoplastic Combined Chemotherapy Protocols,therapeutic use,Benzamides,Biological Markers,metabolism,Erdheim-Chester Disease,diagnosis,drug therapy,genetics,Glutamic Acid,Humans,Immunohistochemistry,Interferon-alpha,administration & dosage,Male,Middle Aged,Mutation,Piperazines,Prednisolone,Proto-Oncogene Proteins B-raf,Pyrimidines,Receptor, Platelet-Derived Growth Factor beta,Valine
Antineoplastic Combined Chemotherapy Protocols, therapeutic use, Benzamides, Biological Markers, metabolism, Erdheim-Chester Disease, diagnosis, drug therapy, genetics, Glutamic Acid, Humans, Immunohistochemistry, Interferon-alpha, administration & dosage, Male, Middle Aged, Mutation, Piperazines, Prednisolone, Proto-Oncogene Proteins B-raf, Pyrimidines, Receptor, Platelet-Derived Growth Factor beta, Valine